The 23-year-old reigning French Open champion tested positive for a heart medication, trimetazidine (TMZ), in an out-of-competition sample in August 2024, when she was world number one.
The International Tennis Integrity Agency (ITIA) accepted that it was caused by contamination of the regulated non-prescription medication melatonin, manufactured and sold in Poland, which Swiatek took for jet lag and sleep issues.
Swiatek’s level of fault was therefore considered to be at the lowest end of the range for ‘No Significant Fault or Negligence’.
“In the last two-and-a-half months I was subject to strict ITIA proceedings, which confirmed my innocence,” she said on Instagram.
“The only positive doping test in my career, showing unbelievably low level of a banned substance I’ve never heard about before, put everything I’ve worked so hard for my entire life into question.
“Both me and my team had to deal with tremendous stress and anxiety. Now everything has been carefully explained, and with a clean slate I can go back to what I love most.”
Swiatek was provisionally suspended from 12 September before successfully appealing, missing three tournaments.
The Polish player appealed the provisional suspension on 22 September, notifying an independent tribunal that the source of the positive test had been identified as a contaminated medicine manufactured in her home country.
After testing confirmed Swiatek’s account, the ITIA offered her a one-month suspension which she accepted on Wednesday.
Because her provisional suspension was lifted on 4 October, Swiatek’s period of ineligibility will end on 4 December 2024.
Leave a Reply